



GARS® Test References

Allelic association of human dopamine D2 receptor gene in alcoholism.

Blum K, Noble EP, Sheridan PJ. JAMA. 1990;263(15):2055–2060.

Dopamine Genetics and Function in Food and Substance Abuse.

Blum K, Oscar-Berman M, Barh D, Giordano J, Gold M, J Genet Syndr. Gene Ther. 2013;4(121) pii: 1000121.

Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS®) as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric.

Blum K, Febo M, McLaughlin T, Cronjé FJ, Han D, Gold MS. J Behav Addict. 2014;3(3):149–156.

Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations.

Arch Gen Psychiatry. 2004;61(6):597–606.

Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)?

Blum K, Oscar-Berman M, Jacobs W, McLaughlin T, Gold MS. J Addict Res Ther. 2014;5.

What can the DRD2/alcoholism story teach us about association studies in psychiatric genetics?

Am J Med Genet. 1995;60(4):272–275. Blum K, Downs BW, Dushaj K, et al.

The benefits of customized DNA directed nutrition to balance the brain reward circuitry and reduce addictive behaviors.

Precis Med (Bangalore) 2016;1(1):18–33.

Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: a preliminary report.

Chen AL, Blum K, Chen TJ, Giordano J, Downs BW, Han D, Barh D, Braverman ER.

LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome.

Blum K, Chen AL, Chen TJ, Rhoades P, Prihoda TJ, Downs BW, Waite RL, Williams L, Braverman ER, Braverman D, Arcuri V, Kerner M, Blum SH, Palomo T.

Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map?

Downs BW, Chen AL, Chen TJ, Waite RL, Braverman ER, Kerner M, Braverman D, Rhoades P, Prihoda TJ, Palomo T, Oscar-Berman M, Reinking J, Blum SH, DiNubile NA, Liu HH, Blum K.

Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS).

Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mangucci JF, Braverman ER, Arcuri V, Deutsch R, Pons MM. Med Hypotheses. 2007;68(4):844-52. Epub 2006 Oct 27.

Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report.

Blum K, Braverman ER, Wood RC, Gill J, Li C, Chen TJ, Taub M, Montgomery AR, Sheridan PJ, Cull JG.

Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour.

Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE. Pharmacogenetics. 1995 Jun;5(3):

Coupling Neurogenetics (GARS®) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.

Blum K, Simpatico T, Badgaiyan RD, Demetrovics Z, Fratantonio J, Agan G, Febo M, Gold MS.

Genetic Addiction Risk Score (GARS®): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).

Blum K, Oscar-Berman M, Demetrovics Z, Barh D, Gold MS.

Dopamine Genetics and Function in Food and Substance Abuse.

Blum K, Oscar-Berman M, Barh D, Giordano J, Gold M.

Coupling Genetic Addiction Risk Score (GARS®) with Electrotherapy: Fighting Iatrogenic Opioid Dependence.

Blum K, Oscar-Berman M, Dinubile N, Giordano J, Braverman ER, Truesdell CE, Barh D, Badgaiyan R.

THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS.

Blum K, Downs BW, Dushaj K, Li M, Braverman ER, Fried L, Waite R, Demetrovics Z, Badgaiyan R

Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.

Blum K, Oscar-Berman M, Giordano J, Downs B, Simpatico T, Han D, Femino J.

Genetic addiction risk score (GARS®), a predictor of vulnerability to opioid dependence.

Blum K, Chen ALC, Thanos PK, Febo M, Demetrovics Z, Dushaj K, Kovoov A, Baron D, Smith DE, Roy AK III, Fried L, Chen TJH, Chapman E Sr, Modestino EJ, Steinberg B, Badgaiyan RD.

Coupling Genetic Addiction Risk Score (GARS®) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD).

Blum K, Madigan MA, Fried L, Braverman ER, Giordano J, Badgaiyan RD.

GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM™): LESSONS LEARNED FROM AMERICA.

Blum K, Modestino EJ, Gondré-Lewis MC, Neary J, Siwicki D, Hauser M, Barh D, Steinberg B, Badgaiyan RD.

Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).

Blum K, Febo M, Fried L, Li M, Dushaj K, Braverman ER, McLaughlin T, Steinberg B, Badgaiyan RD.